An enhancer demethylator phenotype converged to immune dysfunction and resistance to immune checkpoint inhibitors in clear-cell renal cell carcinomas.
Fiche publication
Date publication
novembre 2022
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DAVIDSON Irwin, Pr LANG Hervé, Dr LINDNER Véronique, Pr MALOUF Gabriel, Dr TRICARD Thibault
Tous les auteurs :
Lu X, Vano Y, Helleux A, Su X, Lindner V, Davidson G, Mouawad R, Spano JP, Roupret M, Elaidi R, Compérat E, Verkarre V, Sun C, Chevreau C, Bennamoun M, Lang H, Tricard T, Cheng W, Xu L, Davidson I, Yan F, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG
Lien Pubmed
Résumé
Immune checkpoint inhibitors have revolutionized the treatment of patients with clear-cell renal carcinomas (ccRCC). Although, analyses of transcriptome, genetic alterations, and the tumor microenvironment have shed light into mechanisms of response and resistance to these agents, the role of epigenetic alterations in this process remains fully unknown.
Référence
Clin Cancer Res. 2022 11 14;: